Your browser doesn't support javascript.
loading
Impact of removal and restriction of me-too medicines in a hospital drug formulary on in- and outpatient drug prescriptions: interrupted time series design with comparison group.
Vázquez-Mourelle, Raquel; Carracedo-Martínez, Eduardo; Figueiras, Adolfo.
Afiliação
  • Vázquez-Mourelle R; Sub-Directorate-General, Galician Health Service (Servicio Gallego de Salud - SERGAS), Galicia Regional Authority, Santiago de Compostela, Galicia, Spain. raquel.vazquez.mourelle@sergas.es.
  • Carracedo-Martínez E; Santiago de Compostela Health Area Authority, Galician Health Service, Santiago de Compostela, Galicia, Spain.
  • Figueiras A; Department of Preventive Medicine and Public Health, Faculty of Medicine, University of Santiago de Compostela and Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología y Salud Pública - CIBERESP), Santiago de Compostela, Galicia, Spain.
Implement Sci ; 14(1): 75, 2019 07 24.
Article em En | MEDLINE | ID: mdl-31340835
ABSTRACT

BACKGROUND:

The study covered in- and out-of-hospital care in a region in north-western Spain. The intervention evaluated took the form of a change in the hospital drugs formulary. Before the intervention, the formulary contained four of the five low molecular weight heparins (LMWHs) marketed in Spain. The intervention consisted of withdrawing two LMWHs (bemiparin and dalteparin) from the formulary and restricting the use of another (tinzaparin), leaving only enoxaparin as an unrestricted prescription LMWH. Accordingly, the aim of this study was to evaluate the effect on in- and outpatient drug prescriptions of removing and restricting the use of several LMWHs in a hospital drugs formulary.

METHODS:

We used a natural, before-after, quasi-experimental design with a control group and monthly data from January 2011 to December 2016. Based on data drawn from official Public Health Service sources, the following dependent variables were extracted defined daily doses (DDD) per 1000 inhabitants per day (DDD/TID), DDD per 100 stays per day, and expenditure per DDD.

RESULTS:

The two compounds that were removed from the formulary registered an immediate decrease at both an intra- and out-of-hospital level (66.6% and 55.6% for bemiparin and 73.0% and 92.2% for dalteparin, respectively); similarly, the compound that was restricted also registered an immediate decrease (36.1% and 9.0% at the in- and outpatient levels, respectively); in contrast, the remaining LMWH (enoxaparin) registered an immediate, significant increase at both levels (44.9% and 32.6%, respectively). The intervention led to an immediate reduction of 6.8% and a change in trend in out-of-hospital cost/DDD; it also avoided an expenditure of €477,317.1 in the 21 months following the intervention.

CONCLUSIONS:

The results indicate that changes made in a hospital drugs formulary towards more efficient medications may lead to better use of pharmacotherapeutic resources in its health catchment area.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Prescrições de Medicamentos / Enoxaparina / Heparina de Baixo Peso Molecular / Uso de Medicamentos / Análise de Séries Temporais Interrompida / Formulários de Hospitais como Assunto Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Prescrições de Medicamentos / Enoxaparina / Heparina de Baixo Peso Molecular / Uso de Medicamentos / Análise de Séries Temporais Interrompida / Formulários de Hospitais como Assunto Idioma: En Ano de publicação: 2019 Tipo de documento: Article